Forte Biosciences, Inc. (FBRX)
| Previous Close | 0.6320 |
| Open | 0.6000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.5612 - 0.6290 |
| 52 Week Range | 0.3800 - 1.0600 |
| Volume | |
| Avg. Volume | 26,156 |
| Market Cap | 21.865M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
DALLAS, May 17, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
- Business Wire
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
DALLAS, May 13, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update.
- Business Wire
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
